KT-621 for Asthma

(BREADTH-EXT Trial)

This trial tests a treatment called KT-621, a new potential drug, to evaluate its long-term safety and effectiveness for people with asthma. The researchers aim to understand how KT-621 functions in the body and whether it continues to manage asthma symptoms safely. The study specifically targets participants who have completed a previous KT-621 study. Those who finished the earlier study and can attend all visits and tests might find this trial suitable. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

Research has shown that KT-621 demonstrates promising safety results from earlier studies. In trials with healthy volunteers, participants tolerated KT-621 well, and no major side effects emerged. Participants took KT-621 as a once-a-day pill, and the safety results exceeded expectations. Additionally, tests in asthma models showed KT-621 worked similarly to existing treatments like dupilumab, which is already approved. These findings suggest that KT-621 could be a safe option for those considering joining a clinical trial.¹²³⁴⁵

Unlike the standard treatments for asthma, which often include inhaled corticosteroids and bronchodilators, KT-621 works differently by targeting specific pathways involved in the inflammatory response. Researchers are excited about KT-621 because it has a novel mechanism of action that may provide more effective control of asthma symptoms with potentially fewer side effects. This innovative approach could offer new hope for patients who do not respond well to existing therapies.

Research has shown that KT-621, the investigational treatment in this trial, could be a promising option for asthma. In studies with mice, KT-621 not only prevented asthma from worsening but also improved existing symptoms. Early human studies demonstrated a significant reduction in a key asthma marker called FeNO, which measures airway inflammation, by 25% and 33% in different dose groups. KT-621 breaks down a protein called STAT6, involved in allergies and asthma, and proved effective even at low doses. Patients tolerated it well. These findings suggest that KT-621 could be an effective new treatment for asthma.²⁵⁶⁷⁸